Cancer Research Fund of Contra Costa

Triton Biosciences Inc.

David J Larocca

Jerry A Peterson

Roberto L Ceriani

John J Monahan

Terence K Brunck

Robeto L Ceriani

A polypeptide has the antibody binding activity of the 46 Kdalton HMFG differentiation antigen and/or homology to at least one of the light chains of clotting factors V and VIII and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof in vivo and in vitro methods for therapy vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and/or polypeptides of the invention.

Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method

A fusion protein comprises a sequence of amino acids which binds antibodies specific to the human milk fat globule (HMFG) differentiation antigens. Specific amino acid sequences are provided, and a fusion protein may be used as an immunogen and for diagnostic purposes.

Fusion protein containing HMFG Epitop E (S)

A polypeptide has the antibody binding activity of the 46 Kdalton HMFG antigen and/or homology to at least one of the light chains of clotting factors V and VIII and/or contains RGD and/or EGF-like segments. The polypeptide is provided as a recombinant and/or glycosylated and/or fusion protein. An antibody has high affinity for specificity epitopes of the polypeptide of the invention. Polynucleotide segments encode the polypeptide, recombinant and fusion protein of the invention or fragments thereof, and immunoassay kits comprise the antibodies and/or polypeptides of the invention and other components. In vivo, ex vivo, and in vitro methods of therapy, vaccination and diagnosis utilize the polypeptide, fusion protein anti-sense nucleotides, antibodies or and polynucleotides of the invention.

46 kilodalton human milk fat globule (HMFG) antigen, fragments and

A polypeptide has the antibody binding activity of the 70K dalton HMFG differentiation antigen and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof. in vivo and in vitro methods for therapy, vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and/or polypeptides of the invention.

Nucleic acids and vector encoding HMFQ polypeptide, transfected host,

An in vitro solid-phase, competitive assay for detecting the presence of a peptide analyte in a biological sample comprises contacting a fusion protein, of first and second peptides, with a solid supported first antibody or fragment thereof, which binds the first peptide, adding a biological sample containing the peptide analyte and a second antibody or fragment thereof which binds the peptide analyte and the second peptide. The second antibody is allowed to bind any free analyte present in the sample, and to form solid supported complexes of fusion protein and antibody. The amount of solid supported second antibody detected is then compared to a control. When the amount of peptide analyte in the sample increases the amount of second antibody bound to the solid support decreases. An optional final addition of an antibody-binding molecule helps detect the solid supported complexes of the fusion protein and the second antibody or fragment. The assay may be utilized for detecting neoplastic antigens from tumors or their metastases by using a second peptide that binds specifically to an antibody specific to an antigen, such as an epithelial mammary cell antigen. A kit for detecting the presence of neoplastic tissue comprises the fusion protein, a first antibody or fragment thereof specifically binding the first peptide, and a second antibody or fragment thereof specifically binding the second peptide, and optionally a device for detecting the second antibody or fragment thereof, such as a labeled antibody-binding molecule.

Solid-phase competitive assay utilizing a fusion protein

An in vitro solid-phase, competitive assay for detecting the presence of a peptide analyte in a biological sample, comprising contacting a fusion protein made of a first peptide and a second peptide to a solid supported first antibody which specifically binds to the first peptide, adding thereto a biological sample containing a peptide analyte, adding a second antibody specifically binding to the analyte and the second peptide, and allowing the second antibody to bind any free analyte present in the sample and the solid supported fusion protein to form analyte-second antibody and solid supported fusion protein-second antibody complexes, and determining the amount of solid supported second antibody present and comparing it to a control. When the amount of peptide analyte in the sample increases the amount of a second antibody bound to the solid support decreases. An optional final addition of an antibody-binding molecule helps detect the antibody-fusion protein complex bound to the solid support. The assay may be utilized for detecting neoplastic antigens from tumors or their metastases by utilizing a fusion protein containing an antigen of an epithelial mammary cell. A kit for detecting the presence of a neoplastic tissue comprises the fusion protein along with a first antibody specifically binding to the first peptide, and a second antibody specifically binding to the second peptide, and optionally a means for detecting the second antibody or fragment thereof, such as an antibody-binding molecule.

Highly sensitive and specific solid-phase competitive assay utilizing a

A polypeptide has the antibody binding activity of the 46K dalton HMFG differentiation antigen and/or homology to at least one of the light chains of clotting factors V and VIII and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof. in vivo and in vitro methods for therapy vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and/or polypeptides of the invention.

Polypeptide with 46 Kdalton HMFG differentiation antigen binding

The mRNA coded by the 'anti-sense' strand of the complementary DNA produced by HTLV-I infection contains significant open reading frames. Cells infected by HTLV-I virus produce mRNA that is anti-sense to the viral RNA genome. Infected cells may produce proteins from the newly discovered mRNA. The production of the anti-sense in mRNA initiates from a newly discovered transcriptional promoter located within 1.8 kb from the 3' terminus of the viral genome. The mRNA, protein, and antibodies directed thereto can be used in the prevention, diagnosis, and treatment of HTLV-I infections.

Growing community of inventors

San Leandro, CA, United States of America

David J Larocca